Regulation of BECN1-mediated autophagy by HSPB6: Insights from a human HSPB6S10F mutant.
Guan-Sheng LiuHongyan ZhuWen-Feng CaiXiaohong WangMin JiangKobina EssandohElizabeth VafiadakiKobra HaghighiChi Keung LamGeorge GardnerGeorge AdlyPersoulla A NicolaouDespina SanoudouQiangrong LiangJack RubinsteinGuo-Chang FanEvangelia G KraniasPublished in: Autophagy (2018)
HSPB6/Hsp20 (heat shock protein family B [small] member 6) has emerged as a novel cardioprotector against stress-induced injury. We identified a human mutant of HSPB6 (HSPB6S10F) exclusively present in dilated cardiomyopathy (DCM) patients. Cardiac expression of this mutant in mouse hearts resulted in remodeling and dysfunction, which progressed to heart failure and early death. These detrimental effects were associated with reduced interaction of mutant HSPB6S10F with BECN1/Beclin 1, leading to BECN1 ubiquitination and its proteosomal degradation. As a result, autophagy flux was substantially inhibited and apoptosis was increased in HSPB6S10F-mutant hearts. In contrast, overexpression of wild-type HSPB6 (HSPB6 WT) not only increased BECN1 levels, but also competitively suppressed binding of BECN1 to BCL2, resulting in stimulated autophagy. Indeed, preinhibition of autophagy attenuated the cardioprotective effects of HSPB6 WT. Taken together, these findings reveal a new regulatory mechanism of HSPB6 in cell survival through its interaction with BECN1. Furthermore, Ser10 appears to be crucial for the protective effects of HSPB6 and transversion of this amino acid to Phe contributes to cardiomyopathy.
Keyphrases
- heat shock protein
- heat shock
- wild type
- heart failure
- cell death
- oxidative stress
- endoplasmic reticulum stress
- stress induced
- signaling pathway
- endothelial cells
- end stage renal disease
- magnetic resonance
- newly diagnosed
- heat stress
- left ventricular
- computed tomography
- ejection fraction
- chronic kidney disease
- genome wide
- transcription factor
- cell cycle arrest
- peritoneal dialysis
- prognostic factors
- single cell
- patient reported outcomes
- pluripotent stem cells
- contrast enhanced